Integrating non-clinical and clinical evidence for prioritisation in paediatric oncology drug development: Regulatory experience with three PARP inhibitors

EJC Paediatric Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles